Mwandishi:
Mhariri:
Imeboreshwa;
ULY CLINIC
ULY CLINIC
27 Oktoba 2026, 13:25:33
Sickle cell disease: chronic pain, hypersplenism, bone and joint complications
Sickle cell disease: chronic pain, hypersplenism, bone and joint complications
Chanzo: National Sickle Cell Disease Management Guidelines, Ministry of Health Tanzania. Toleo: 2nd edition, June 2026. Mwongozo wa Taifa (supporting guideline).
Chronic pain
Chronic pain is pain lasting 3 months or more. It may occur with or without objective signs of avascular necrosis, arthropathy, arthritis, leg ulcers or vertebral body collapse.
In addition to the pain management guideline (companion article "Sickle cell disease: pain relief and morphine management"):
Investigate and manage the underlying cause of the pain.
Encourage activities that relieve pain, e.g. deep pressure massage, muscle relaxation therapy, yoga and hydrotherapy.
For neuropathic pain consider an antineuralgic (e.g. gabapentin or carbamazepine) or a tricyclic antidepressant (e.g. amitriptyline).
Use long-acting (e.g. morphine extended-release capsules, tramadol) and short-acting opioids for chronic pain not relieved by non-opioids.
Refer patients with progressive musculoskeletal conditions to an orthopaedic or rheumatology specialist.
Refer to a psychologist for anxiety or depression arising from disability, job absence or financial difficulties.
Refer to an occupational therapist and physiotherapist to help the patient reach the best physical function and independence.
Hypersplenism
Hypersplenism is splenomegaly with cytopenia of at least two cell lines.
Symptoms and signs: pallor, lethargy; abdominal distension with chronic splenomegaly; cytopenia.
Investigations: full blood picture; reticulocyte count; peripheral smear; iron studies; bone marrow aspirate (if the reticulocyte count is low); PT/PTT/INR (if splenectomy is anticipated).
Management:
Exclude and treat all causes of anaemia.
Transfuse if Hb is below 4 g/dL.
Monitor and document the spleen size at every visit.
Refer to the surgical department for elective splenectomy.
Avascular necrosis (AVN)
AVN causes chronic pain and limited movement because of joint damage (rather than ongoing vaso-occlusion). It commonly affects the femoral head (hip) or humeral head (shoulder). Adolescents are commonly affected, but it may start in early childhood.
Symptoms and signs: severe pain and reduced mobility; pain on internal or external rotation of the joint; reduced ability to abduct the joint; an antalgic gait (favouring weight bearing on the unaffected side).
Investigations: plain X-ray; MRI (shows changes earlier than X-ray).
Management:
Non-steroidal anti-inflammatory drugs, with or without codeine derivatives, for acute pain.
Manage chronic pain with the chronic pain measures in this article (pain-relieving activities, neuropathic pain medicines, long- and short-acting opioids, specialist referral).
Rest and avoid weight bearing on the affected joint for at least 3 months.
Non-weight-bearing physiotherapy (refer to a physiotherapist).
Continue hydroxyurea therapy.
Refer for orthopaedic assessment and treatment.
Orthopaedic surgery for avascular necrosis (national guideline notes)
Hip replacement is generally delayed until the mid-20s, because a replacement lasts only 10–20 years and then needs to be replaced.
Tenotomy to improve the range of movement, or osteotomy and/or decompression surgery, can improve the joint before the end of the adolescent growth phase.
Joint replacement may become necessary if the pain is continuous (more than 2 years) or very severe and mobility is seriously affected.
Different prostheses, hip fusion or bone grafting are used depending on the case; cemented prostheses are best avoided (to allow a later "re-do").
Infection and loosening of the prosthesis are common.
Always discuss with the patient before surgery the possibility of failure, the likelihood of some remaining pain, the expected life of the prosthesis and the limitations it imposes.
Give blood transfusion before tenotomy or osteotomy and for 3 months after the operation to maximise bone healing.
Osteomyelitis and septic arthritis
Bacterial infection of bones and joints is common in children and adults with SCD. Common organisms are S. aureus, Salmonella and S. pneumoniae.
Symptoms and signs: vague bone pain; fever (may not persist); inability to walk or limping; persistent signs of inflammation at the site (redness, tenderness, warmth, swelling); draining sinus tracts (in chronic osteomyelitis).
Investigations:
Full blood picture; blood culture and sensitivity; CRP.
X-ray: changes of osteomyelitis do not appear until at least 10 days after onset.
Ultrasound and MRI of the affected bone.
Joint aspiration: useful to identify the organism if fluid is seen on ultrasound.
Management:
IV ceftriaxone 100 mg/kg once daily OR IV amoxicillin-clavulanic acid 30 mg/kg 8-hourly for at least 10 days, then continue with an oral third-generation cephalosporin such as cefixime, or oral amoxicillin-clavulanic acid, to complete at least 3 weeks of treatment.
Consult an orthopaedic surgeon.
Imeandikwa:
27 Oktoba 2026, 13:23:58
Rejea za mada:
1. Ministry of Health Tanzania. National Sickle Cell Disease Management Guidelines, 2nd edition. June 2026. Part III, sections 1–3: Chronic pain, hypersplenism, orthopaedic complications (pages 23–26).
